Search

Author/Creator Joshi, Adarsh

1. 357 TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma. (9th November 2020)

Authors:
Collins, Sabrina; Joshi, Adarsh; Shen, Lei; Das, Subhasree; Suryanarayan, Kaveri; Bottino, Dean; Li, Cheryl; Curley, Michael; Wang, Dannie; Abadier, Michael; Larson, Ryan; Parot, Xavier
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A218
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 357 TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma. (9th November 2020)

Authors:
Collins, Sabrina; Joshi, Adarsh; Shen, Lei; Das, Subhasree; Suryanarayan, Kaveri; Bottino, Dean; Li, Cheryl; Curley, Michael; Wang, Dannie; Abadier, Michael; Larson, Ryan; Parot, Xavier
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A382
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. A phase 2, single‐arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy. Issue 11 (27th February 2014)

Authors:
Garcia, Jorge A.; Hudes, Gary R.; Choueiri, Toni K.; Stadler, Walter M.; Wood, Laura S.; Gurtler, Jayne; Bhatia, Shailender; Joshi, Adarsh; Hozak, Rebecca R.; Xu, Yihuan; Schwartz, Jonathan D.; Thompson, John A.
Journal:
Cancer
Issue:
Volume 120:Issue 11(2014)
Page Start:
1647
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. A phase 2, single‐arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy. Issue 11 (27th February 2014)

Authors:
Garcia, Jorge A.; Hudes, Gary R.; Choueiri, Toni K.; Stadler, Walter M.; Wood, Laura S.; Gurtler, Jayne; Bhatia, Shailender; Joshi, Adarsh; Hozak, Rebecca R.; Xu, Yihuan; Schwartz, Jonathan D.; Thompson, John A.
Journal:
Cancer
Issue:
Volume 120:Issue 11(2014)
Page Start:
1647
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer. Issue 13 (September 2015)

Authors:
Hussain, Maha; Rathkopf, Dana; Liu, Glenn; Armstrong, Andrew; Kelly, Wm. Kevin; Ferrari, Anna; Hainsworth, John; Joshi, Adarsh; Hozak, Rebecca R.; Yang, Ling; Schwartz, Jonathan D.; Higano, Celestia S.
Journal:
European journal of cancer
Issue:
Volume 51:Issue 13(2015:Sep.)
Page Start:
1714
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Safety, Pharmacokinetics and Pharmacodynamics of Selgantolimod, an Oral Toll-Like Receptor 8 Agonist: A Phase Ia Study in Healthy Subjects. Issue 3 (April 2020)

Authors:
Reyes, Maribel; Lutz, Justin D; Lau, Audrey H; Gaggar, Anuj; Grant, Ethan P; Joshi, Adarsh; Mackman, Richard L; Ling, John; Tan, Susanna K; Ayithan, Natarajan; Daffis, Stephane; Woo, Jacky; Wu, Peiwen; Lam, Tina; Fletcher, Simon P; Kottilil, Shyamasundaran; Poonia, Bhawna; Gane, Edward J; Mathias...
Journal:
Antiviral therapy
Issue:
Volume 25:Issue 3(2020)
Page Start:
171
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗